Denis Rylnikov

Dr. Denis Rylnikov

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAlvina Khachatryan
Alvina Khachatryan
DRDenis Rylnikov
Denis Rylnikov
SMSevara Mirakhmedova
Sevara Mirakhmedova
ESEvgeny I. Seliverstov
Evgeny I. Seliverstov
EAEvgeny S. An
Evgeny S. An
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Background: Pulmonary embolism (PE) patients are generally admitted to the hospital, which leads to significant burden on healthcare systems. Many PE patients are hemodynamically stable and can be ambulated safely. Direct oral anticoagulants (DOACs) do not need routine laboratory monitoring, which makes them a convenient option for outpatient care. Data on the outpatient management of PE patients using DOACs are scarce. Methods: We conducted a systematic search of MECENTRAL databases to identify randomized controlled trials (RCTs), non-randomized studies (non-RCTs), retrospective studies, reviews, systematic reviews, meta-analyses, and clinical guidelines evaluating the use of DOACs for outpatient treatment of PE patients. Results: A total of 833 publications were identified, and eight studies—two RCTs and six non-RCTs (two retrospective and four prospective)—were finally included. These studies reported rates of bleeding events, recurrent venous thromboembolism (VTE), PE-related mortality, and all-cause mortality among outpatients who received DOACs. No PE-related deaths were reported in any of the included studies. Bleeding events were reported in five studies, and recurrent VTE rates were reported in two studies. Study findings showed that the sPESI score has some disadvantages in selecting patients for home treatment. The quality of the studies varied considerably. A meta-analysis could not be performed due to heterogeneity in the study designs, patient populations, and outcome reporting. While the treatment results favored outpatient management of selected PE patients, no robust conclusions could be drawn from the published data. Conclusions: Outpatient treatment of PE with DOACs has some potential as an approach for managing selected patients. Hestia, POMPE-C and RESI scores are preferable for selecting PE patients for home treatment, but utilizing sPESI as the only tool has to be avoided. Apixaban and rivaroxaban are both safe, with a low bleeding risk. Large-scale prospective studies are required to establish the efficacy and safety of outpatient PE management using DOACs.

18 March 2024 in Journal of Venous Disorders
Verified
Journal Article
Closed access
DRDenis Rylnikov
Denis Rylnikov
ILI.S. Lebedev
I.S. Lebedev
SYS.M. Yumin
S.M. Yumin
ESE.I. Seliverstov
E.I. Seliverstov
The review is devoted to modern literature data on floating venous thrombosis. Historical data regarding surgical venous disconnection and recanalization are presented. The authors reviewed modern studies devoted to embolism-threatening thrombosis and appropriate international recommendations. Deep vein thrombosis (DVT) of the lower extremities and pelvis is characterized by clotting in appropriate veins. Pulmonary embolism (PE) is the main and life-threatening complication of DVT. Floating thrombosis is believed to be very dangerous for many years and absolutely requires surgical prevention of PE. Nevertheless, appropriate data are contradictory. Most professional communities recognize impossible anticoagulation as the only indication for cava filter implantation. National guidelines (2023) do not recognize proximal floating thrombus as the only indication for cava filter implantation. Unclear role of floating clots as a risk factor for PE forces specialists to continue cava filter implantation in these cases to this day. Importantly, percutaneous cava filter implantation is really not always possible. This fact requires more invasive partial and complete disconnection with higher incidence of complications, such as ligation of superficial femoral vein, plication of inferior vena cava and open thrombectomy. These features inspired us to analyze venous thrombosis as a risk factor of pulmonary embolism.

17 June 2024 in Journal of Venous Disorders
Verified
Journal Article
Closed access
DRDenis Rylnikov
Denis Rylnikov
ESE.I. Seliverstov
E.I. Seliverstov
EAE.S. An
E.S. An
AKA.S. Kuperin
A.S. Kuperin
ILI.S. Lebedev
I.S. Lebedev
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Despite clinical guidelines not recognizing floating clots as an absolute indication for surgical prevention of pulmonary embolism (PE), many specialists adhere to active surgical approach in such cases. OBJECTIVE To evaluate the incidence of symptomatic PE in patients with proximal embolic (floating) thrombus under standard anticoagulation. MATERIAL AND METHODS We analyzed patients with proximal venous thrombosis above the femoral vein. The main group (embolic thrombosis) included 60 patients with floating clot length of 9.3±2.3 cm, the control group (non-embolic thrombosis) — 164 patients with floating clot length of 2.2±2.2 cm (p<0.0001). The main endpoint was the incidence of symptomatic PE after onset of anticoagulation. In-hospital mortality and hospital-stay were also assessed. RESULTS Patients with embolic thrombosis were younger (59.6±14.7 and 64.9±16.4 years, respectively, p=0.029). Proximal level of thrombosis below the inguinal ligament was found in 49 (81.6%) and 102 (62%) patients, respectively (p=0.006). Mean hospital-stay was 9.2±3.3 and 6.0±1.9 days, respectively (p<0.0001). In-hospital PE occurred in 2 (1.2%) patients of the control group. No PE was observed in the main group (p=0.952). There were no deaths in both groups. CONCLUSION Incidence of symptomatic PE is similar in patients with embolic and non-embolic deep vein thrombosis receiving adequate anticoagulation in accordance with clinical guidelines.

26 March 2026 in Journal of Venous Disorders
Verified
Journal Article
Closed access
AKAlvina Khachatryan
Alvina Khachatryan
DRDenis Rylnikov
Denis Rylnikov
RKR.S. Khachyatryan
R.S. Khachyatryan
ESE.I. Seliverstov
E.I. Seliverstov
EAE.S. An
E.S. An
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Objective. To evaluate the efficacy and safety of outpatient treatment of pulmonary embolism (PE) using standard anticoagulant therapy (ACT) with direct oral anticoagulants. Material and methods. A prospective, observational study was conducted in patients with PE. The analysis included fifty patients with a first-time diagnosis of PE who received outpatient treatment. Outpatient management was defined as discharge from the emergency (diagnostic) department after completion of additional evaluation and confirmation of PE. The primary outcomes were the incidence of symptomatic recurrent venous thromboembolism (VTE) and bleeding events following initiation of ACT. Secondary outcomes included VTE-related mortality and all-cause mortality, readmission to emergency departments, and non-adherence to ACT. Results. The mean age of patients was 65±10 years, with a predominance of women (n=29; 58%). The most common presenting symptoms were lower extremity edema (24%) and dyspnea (16%). PE involved the segmental and subsegmental pulmonary arteries in 84% of patients, submassive PE was diagnosed in 10% of subjects, and massive PE — in 4%. Furthermore, 44 (88%) of patients developed PE in addition to oncological disease. Recurrent VTE within 3 months was observed in 1 (2%) patient. No major or clinically relevant bleeding events occurred, and minor bleeding was reported in 1 (2%) patient. Non-adherence to ACT was noted in 2 (4%) patients. During the study, five deaths (10%) occurred, none of which were VTE-related. Conclusion. Outpatient management of hemodynamically stable patients with pulmonary embolism is effective and safe when proper risk stratification and careful evaluation of individual complication risks are ensured.

27 December 2025 in Journal of Venous Disorders
Verified
Journal Article
Closed access
DRDenis Rylnikov
Denis Rylnikov
AKAlvina Khachatryan
Alvina Khachatryan
EDE.A. Duenina
E.A. Duenina
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Venoactive Drugs (VADs) are an integral part of the conservative management of chronic venous diseases (CVD). The mechanism of action of these drugs is well-described. It targets key ways of pathogenesis of CVD, such as loss of venous tone, chronic inflammation in the venous wall and its subsequent remodeling, increased capillary permeability, and insufficient compensatory function of the lymphatic system. The clinical efficacy of VADs concerning quality of life, CVD signs and symptoms, has been demonstrated in numerous randomized controlled trials (RCTs), meta-analyses, and systematic reviews. The incidence of adverse events appears to be low, and the use of VADs is considered a safe method of treatment for CVD symptoms. The most extensively studied group of VADs are flavonoids, which include drugs based on diosmin and rutosides. Diosmin, a principal flavonoid used in drugs, exhibits pleiotropic effects. It slows the degradation of norepinephrine in the venous wall, potentiating its effect and enhancing venous tone. Diosmin possesses anti-inflammatory activity by inhibiting leukocyte adhesion and the synthesis of pro-inflammatory mediators. It decreases capillary and venule permeability, which is directly associated with reduced fluid movement into the tissues. RCTs show that diosmin is effective in managing diseases of other organs and systems which also present with edema.

13 September 2024 in Journal of Venous Disorders
Verified
Journal Article
Closed access
DRDenis Rylnikov
Denis Rylnikov
ESE.I. Seliverstov
E.I. Seliverstov
EAE.S. An
E.S. An
AKA.S. Kuperin
A.S. Kuperin
ILI.S. Lebedev
I.S. Lebedev
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Objective. To assess the effect of the adequacy of anticoagulant therapy (ACT) on the risk of pulmonary embolism (PE) in patients with proximal deep vein thrombosis. Material and methods. The analysis of a database consisting of 223 patients with proximal venous thrombosis (the thrombus location was not lower than the superficial femoral vein) was carried out. The types of detected ACT flaws and their frequency were analyzed. The role of ACT flaws in episodes of bleeding, thrombosis progression, PE, and deaths was evaluated. Results. Of the 223 patients, there were 97 women (43.5%) and 126 men (56.5%). The mean age was 63.4±16.2 years, the average hospital stay was 6.8±2.7 days. Flaws in the ACT were found in 36.3% (81 people) of cases. Among the identified flaws were: an increase in activated partial thromboplastin time (aPTT) by more than 2.5 times — 12 (5.4%) patients, lack of aPTT control in the first 3 days with unfractionated heparin (UFH) therapy — 40 people (17.9%), lack of achievement of target aPTT values in the first 3 days with UFH therapy — 20 people (13%), therapy with a reduced dose of rivaroxaban 20 mg / day in the acute phase of thrombosis without indications for dose reduction — 2 people (1.3%). 2 episodes of symptomatic PE have been recorded. In the first case, there were no ACT flaws, in the second, clinical manifestations of PE occurred in a patient receiving UFH with aPTT values equal to 26—27 seconds. There were no deaths and bleedings. In 40 patients (17.9%), an increase in the level of thrombosis was recorded against the background of ACT. The results of the logistic regression analysis showed that a statistically significant factor in increasing the level of thrombosis is the start of an act with UFH — the odds ratio is 2.52 (95% CI: 1.11—5.74) (p=0.0271). Conclusion. Most often, ACT flaws occur when UFH is prescribed due to its poorly predictable pharmacokinetics and the need for laboratory monitoring. Even though the performed ACT often has defects, it is still able to prevent the progression of VTE in most cases. Even an adequate ACT is not guaranteed to prevent an embolism.